Category - Developments

Developments

Elucid raises $80-million in Series C round

Closely-held Elucid raised $80-million to drive the commercialization of its AI-powered cardiovascular diagnostic tools. The round was led by Elevage Medical Technologies. Elucid’s FDA-cleared software is a non-invasive...

November 9, 2023

Developments

Profound Medical’s TULSA gets device-intensive status; CMS extension of temporary C Code to ambulatory surgical center setting

Profound Medical (NASDAQ:PROF; TSX:PRN) reported that the U.S. Centers for Medicare and Medicaid Services (CMS) has expanded TULSA’s HCPCS C code, C9734, for use in the ambulatory surgical center (ASC) setting...

November 3, 2023

Developments

Hepion’s rencofilstat demonstrates anti-cancer activity in hepatitis C-associated cancer model

Hepion Pharmaceuticals (NASDAQ:HEPA) published a new research study in mice where rencofilstat prevented the growth of human hepatitis C virus (“HCV”)-associated liver tumors. HCV-infected mice developed small liver...

October 25, 2023

Developments

PharmaJet launches Nigerian study of Tropis-administered poliovirus vaccine

PharmaJet launched a study in Nigeria to evaluate the intradermal administration of a fractional inactivated poliovirus vaccine (fIPV) using the company’s Tropis ID Needle-free Injection System. Children at 22 urban and...

October 25, 2023

Developments

Personalis presents positive NeXT Personal assay data in early-stage lung cancer

Personalis (NASDAQ:PSNL) presented positive data on its NeXT Personal platform’s ability to detect and monitor residual and recurrent disease (MRD) in patients with early-stage lung cancer. NeXT Personal is a whole...

October 23, 2023

Developments

Anixa Biosciences appoints Dr. Mark Goldberg to Cancer Business Advisory Board

Anixa Biosciences (NASDAQ:ANIX) appointed Dr. Mark Goldberg as the ninth independent member of the company’s Cancer Business Advisory Board (CBAB). “Mark brings valuable clinical expertise in oncology, and his extensive...

October 23, 2023

Developments

Profound Medical’s TULSA-PRO prostate cancer treatment featured by AARP as medical breakthrough

Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO technology was featured as a medical breakthrough in an Oct. 13 AARP article. The article introduces 57-year-old Tommy Saul, who was diagnosed with prostate cancer in...

October 13, 2023

Developments

Anixa Biosciences completes first cohort in ovarian cancer CAR-T clinical trial

Anixa Biosciences (NASDAQ:ANIX), in partnership with Moffitt Cancer Center, completed treatment of the first patient cohort in the ongoing clinical trial of Anixa’s novel chimeric antigen receptor T-cell (CAR-T) therapy...

October 13, 2023

Developments

Sigyn Therapeutics submits international patent application for ChemoPrep and ChemoPure

Sigyn Therapeutics (OTCQB:SIGY) submitted a Patent Cooperation Treaty (PCT) application for the technologies it is developing to enhance the clinical benefit of chemotherapeutic drugs. Chemotherapy is the most commonly...

October 5, 2023

Developments

Anixa’s breast cancer vaccine featured in Yahoo Life news

Anixa Biosciences’ (NASDAQ:ANIX) breast cancer vaccine was featured in an Oct. 3 article in Yahoo Life news. The article introduces Ohioan Jennifer Davis as the first person in the world to receive a breast cancer...

October 4, 2023

Category - Developments

Subscribe